Seattle Genetics (SGEN) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Seattle Genetics Reports Second Quarter 2017 Financial Results
July 27, 2017 4:02 PM EDT-Second Quarter 2017 Revenues Were $108.2 Million, Including $74.3 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Sales-
-Positive Top-Line Data from ADCETRIS Phase 3 ECHELON-1 Trial; Full Data to be Submitted for Presentation at ASH Annual Meeting-
-Submission of Supplemental Biologics License Application for FDA Approval of ADCETRIS in Frontline Advanced Hodgkin Lymphoma Planned by End of 2017-
-ADCETRIS Supplemental Biologics License Application Submitted to FDA for Cutaneous T-Cell Lymphoma-
-Initiation of Pivotal Trial of Enfortumab Vedotin in Metastatic Urothelial... More
